Key result
The FHS-Lpts-CHD-10Y model significantly discriminated the presence of carotid plaques in type 2 diabetic patients compared to a random scoring approach, achieving an AUROC of 0.681.
Why the study?
Do CVD risk assessment models derived from FHS, UKPDS, and ARIC studies accurately predict the presence of carotid plaques in T2DM patients?
Cross-Sectional (n=49)
No
Do CVD risk assessment models derived from FHS, UKPDS, and ARIC studies accurately predict the presence of carotid plaques in T2DM patients?
The FHS-Lpts-CHD-10Y risk model, which incorporates LDL-C, demonstrated significant discriminatory ability for detecting asymptomatic carotid plaques in T2DM patients, suggesting its potential utility as a non-invasive screening tool.
Answers are grounded in this paper and cite their sources.
May support FHS-Lpts-CHD-10Y for plaque screening in T2DM; leaves open prospective validation against hard events.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2013) conducted a cross-sectional in Type 2 diabetes mellitus (n=49). FHS-Lpts-CHD-10Y risk assessment model vs. Random scoring approach was evaluated on Discrimination of carotid plaque presence (AUROC) (AUROC 0.681, 95% CI 0.524-0.838, p=0.042). The FHS-Lpts-CHD-10Y model significantly discriminated the presence of carotid plaques in type 2 diabetic patients compared to a random scoring approach, achieving an AUROC of 0.681.
Synapse has enriched 10 related papers. Consider them for comparative context: